Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma Plc LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 48.00p 46.00p 50.00p - - - 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -24.1 -18.9 - 50

Verona Pharma plc Verona Pharma Plc("verona" Or The "Company")appointment Of Nominated Adviser And Uk Broker

01/05/2019 7:00am

UK Regulatory (RNS & others)

   LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical stage biopharmaceutical 
company focused on respiratory diseases, is pleased to announce the 
appointment of Nplus1 Singer Advisory LLP (together with its associates, 
"N+1 Singer") as nominated adviser and UK corporate broker to the 
Company with immediate effect. 
   For further information contact: 
Verona Pharma plc                                          Tel: +44 (0)20 3283 4200 
 Jan-Anders Karlsson, Chief Executive Officer      
 Victoria Stewart, Director of Communications 
N+1 Singer (Nominated Adviser and UK Broker)               Tel: +44 (0)20 7496 3000 
 Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance) 
 Mia Gardner (Corporate Broking) 
ICR, Inc. (US Media and Investor enquiries)                Tel: +1 203-919-7905 
 Darcie Robinson                                   
 Stephanie Carrington                                       Tel. +1 646-277-1282 
   About Verona Pharma plc 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, ensifentrine (RPL554), is a first-in-class, 
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that 
has been shown to act as both a bronchodilator and an anti-inflammatory 
agent in a single compound. Ensifentrine is currently in Phase 2b 
clinical development for the maintenance treatment of COPD and is 
planned to enter Phase 3 trials for this indication in 2020. Verona 
Pharma is also developing ensifentrine for the treatment of cystic 
fibrosis and asthma. 

(END) Dow Jones Newswires

May 01, 2019 02:00 ET (06:00 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Verona Pharma Chart

1 Year Verona Pharma Chart

1 Month Verona Pharma Chart

1 Month Verona Pharma Chart
Your Recent History
Verona Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191018 06:38:56